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1. Introduction 
Following to completion of human genome project and accomplishment of the entire human 
genome sequence, it rose hopes that cure to many diseases would soon come true. This 
encouraged focusing efforts on the effect of gene expression and the mechanisms by which 
it could affect medicine, among which cancer. However, searches for the genes within 
genome (genome: the entire genes of an organism) whose alteration could be the cause of 
cancer has also been subject of hamper and complications by different mechanisms that 
genes might be transcribed (transcriptome: the entire transcripts of an organism or 
organelles within a specific condition) and subsequently into a variety of functional or 
structural unite known as proteins which can by themselves undergo essential changes [1]. 
As a powerful approach proteomics entails analysis of gene expression at protein 
(translation) and protein related levels such as posttranslational modifications, which 
complement the nucleic acid based level of gene expression. Protein based gene expression 
analysis is done by analyzing the ‘proteome’; the entire protein expressed by a genome in 
cells, their sub-cellular structures such as organelles and tissues at a given time and specific 
condition. As a result, proteome is subject of change with time and condition of the being 
although it is direct product of a genome [2].  
The definition of proteomics has changed greatly over the time. While currently it denotes 
any type of technology that focuses analysis of proteins constituent ranging from a single 
protein to thousands in one experiment, however it was originally attributed to the large 
scale protein analysis, high- throughput separation, and subsequent identification of 
proteins resolved by 2-dimensional polyacrylamide gel electrophoresis (2DE). 2DE is still 
the method of choice for protein separation and identification [2]. In subsequent sections, we 
provided a brief description of 2DE, proteomics, and its application in cancer research, the 
proteins and molecular markers, which were identified in esophageal cancer using this 
methodology.  
www.intechopen.com
 
Esophageal Cancer – Cell and Molecular Biology, Biomarkers, Nutrition and Treatment 
 
80
2. Two Dimensional Electrophoresis (2DE) and protein identification 
The first successful two-dimensional electrophoresis dates to the early 1970s by coupling 
denaturing IEF (isoelectric focusing) with the SDS-PAGE. Due to awkward process of 2DE, 
it was relatively unpublicized in its early advent; however, the story has substantially 
reversed several years later when the astonishing paper that revolutionized application of 
2DE was published by O'Farrell [3]. By developing technical aspects of 2DE, O’Farrell was 
able to resolve hundreds of polypeptides in a single gel and in the same experiment. Since 
then, analysis of complex protein entities by 2DE has significantly improved, as in the late 
1980s, 2DE has reached to a fully developed technique [4]. Though there is always space for 
development, 2DE still is subject of ongoing advancements along with seeking alternative 
methods for combining or replacing 2DE in order to achieve higher protein resolution. 
Nevertheless, the main argument that has put forth application of 2DE is that at present 
other methods are no more powerful as 2DE is or are hard enough to handle protein 
complement of the entire genome. 
2DE is composed of proteins or polypeptides separation in two orthogonally (right angle) 
dimension techniques such that in one dimension separation is done based on isoelectric pH 
point (pI) of protein (or polypeptides) by a process which is called isoelectric focusing (IEF) 
and the second dimension based on their molecular weight. As a result of IEF proteins are 
separated based on their charge. Subsequent to IEF, proteins are further resolved or 
separated in the second dimension based on their molecular weight using sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  
From its early advent a requirement for 2DE was separation and comparison of complex 
protein mixtures with high resolution and reproducibility. The development of immobilized 
pH gradients (IPGs) on strips for IEF has fundamentally improved and solved this 
requirement, allowing intra- and inter-laboratory comparison of the separated protein 
profiles possible. The separated proteins can be detected by staining with dyes or metal ions. 
Silver staining is the most commonly used method for detection of proteins. The method is 
100 folds more sensitive than other dye based staining methods such as Coomassie blue, 
however radiolabeling is still the most sensitive method, which can be used for 
autoradiography or fluorography of proteins (figure1).  
Following to separation of proteins it is required to identify them in downstream process. 
While different methods of protein identification were established during past decades, 
nonetheless, peptide mass fingerprinting in combination with mass spectrometry based 
methods such as MALDI/TOF, MALDI/TOF/TOF, LC/MS/MS mass spectrometry as well 
as other methods which all are based on the mass of amino acids and peptides are 
commonly used for protein identification.  
In addition; nowadays 2DE databases are available and could be used as a replacement or as a 
mean of preliminary analysis of the experimentally obtained 2DE separated and scanned 
polypeptides against such 2DE protein profile provided by databases for a specific cell type, 
organelle, body fluids, or tissues. While such supplementary sources of information are useful 
for primary analysis, however mass spectrometry based methods are still the best mean of 
protein identification with high confidence. The complexity and quantity of data available 
from 2DE gel patterns can be handled by image analysis techniques using automated 
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computer analysis systems, which can provide both qualitative and quantitative information 
for polypeptides resolved in an individual gel and provide pattern matching between gels [2]. 
 
Fig. 1. Detection of proteins as well as modification of which by combining 2DE protein 
separation and mass spectrometry based identification. The figure represents peroxiredoxin 
and its modified form in Jurkat cells in normal cell culture conditions (panel A) or stressed 
with t-Butylhydroperoxide. Cells were lysed, and extracts were separated by two-
dimensional electrophoresis: Linear pH gradient 4 – 8 was used for IEF first dimension and 
SDSPAGE was used for second dimension. Gels were subsequently stained with silver-
nitrate. Arrows indicate the position of the normal (prx2NL) and the oxidized (prxOX) 
forms of peroxiredoxin 2. The change in pI (0.25 pH units) is due to the sole oxidation of the 
–SH group in peroxiredoxin 2 (adapted from Rabilloud, et al [4]). 
3. Low abundance proteins and organelle proteomics 
Although large-scale proteome analysis provides valuable information regarding cultured 
cells, tissues, or body fluids; nevertheless, analysis of the whole proteome might be too 
complex even at cellular level [5]. There are many proteins with low copy number, which 
might be far from resolution of the current methods when the whole tissue or cell is used as 
the source of proteins. Such proteins require enrichment before analysis. Considering the 
large variation in the expression level of proteins within a cell or tissue, the low abundance 
proteins become inevitably masked by high abundance proteins [6]. It should be noted that 
most regulatory proteins such as kinases, GTPases, certain membrane receptors, 
polymerases as well as transcription factors are present in low copy number. As a result an 
important layer of information would be lost [7]. This becomes even more important when 
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there is only limited amount of material available for analysis (e.g. medical biopsies). 
Although genomic approaches have benefited from amplification methods such as 
polymerase chain reaction, protein based methods are poor in this regard as there is not 
currently any method available for their amplification. This drawback was solved in part by 
availability and application of accurate methods of identification such as mass spectrometry 
that require infinitesimal amount of proteins and to some extent using enrichment methods 
of low abundance proteins of interest by methods such as chromatography. For example, 
the total protein content of cells can be enriched by fractionation methods based on affinity 
procedures to isolate groups of proteins displaying similar features (lectin based isolation of 
glycoproteins, charge and hydrophobicity based protein separation or application of specific 
antibodies for isolation of phosphoproteins, etc.). This procedure has the advantage of 
simplifying the complexity of crude cell or tissue extracts, thereby maximizing the 
probability of detecting low abundance proteins. However, it should be noted that 
information with regard to the location of the protein of interest in the cell, organ or tissue 
remains to be elucidated. Organizing eukaryotic cells into sub-compartments with 
specialized features and functions; the organelles, provides a unique opportunity to link 
proteomics data with functional units. In addition identification of a specific protein within 
a specific organelle not only would be a step forward in our understanding of the function 
of the protein of interest and the molecular mechanisms in which it is involved but also the 
functional features of the related organelle as well. So far protein profile of several 
organelles have been elucidated by proteomic [5,7]. 
4. Proteomics in cancer research 
Cancer is well known for its complex nature, which results from accumulation of numerous 
molecular alterations altogether lead to genetic instability, cellular proliferation, and 
acquisition of invasive phenotype and metastasis. While it has long been known that cancer 
to be a genetic disorder, but at functional level, it is rather a protein and proteomics related 
disease, since tumor progression, invasion and metastasis all depend on functional identity 
of cells or proteins such as growth factors, transcription factors, enzymes, signal 
transducers, proteases, etc. As a result different kinds of drugs that target different cellular 
components either protein [8] or nucleic acid constituent of the cells have so far been 
designed for treating the disease. Nonetheless such a broad range of drug could not lead to 
a satisfactory progress in complete treatment of the disease. 
Despite our deeper understanding of the alterations and aberrations that happens in cancer 
cells along with advances in characterizing diversity of cancer transcriptomics, proteomics 
has the potential to complement further expansion the wealth of present information 
generated by genomics in cancers from different aspects. These aspects include; (i) there is 
generally not a direct correlation between level of transcription of specific genes and relative 
abundances of their corresponding proteins, since the resultant transcript might be subject 
of degradation, inactivation, or being kept in silent and inactive form until the time it is 
required (RNA granules) [9] (ii) due to the differential splicing and translation, each gene 
may encode several different protein variants with different properties; (iii) the key proteins 
driving malignant behavior of cancer cells can undergo post-translational modifications 
including phosphorylation, acylation, and glycosylation; and (iv) proteome reflects dynamic 
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changes, it could be a suitable indicator of the disease progression and could be used for 
monitoring and following up the course and response of the disease to the therapy. And 
finally proteins represent the more accessible and relevant therapeutic targets [10,11].  
Despite efforts and successes in prevention of cancers through applying screening programs 
along with public awareness, changes in habits, and application of better treatment strategies 
as well as postoperative programs, nevertheless, there wasn’t so far prospect for a long life in 
case of many patients and cancer still remains the major cause of patients’ death. The major 
cause of cancer death is metastasis. In most cases diagnosis of cancer and treatment of which is 
done when tumor has been developed well, metastasis has happened, and tumor has spread 
into distant organs. Proteomics could play important role not only in the study of molecular 
mechanism of carcinogenesis but also discovery of new cancer markers for early diagnosis of 
the disease, staging in addition to evaluating prognosis, prediction and monitoring of patients’ 
response to a particular therapy. Such markers could directly be released from cancer cells or 
may represent as part of host’s response to malignancy. They might be released into body 
fluids, which make their detection easy. Cells most often shed proteins into extracellular fluids 
including interstitial fluids, lymph and blood plasma. Whilst tissue interstitial fluids are in 
direct contact with tissue/cells via transfer of molecules, the composition of blood plasma 
results from its interaction with tissue’s interstitial fluids. Blood plasma is dynamic; it 
influences the composition of other body fluids and becomes influenced by body fluids as 
well. It is important to realize that relative concentration of biomarkers is highest in the tissue 
of origin and surrounding interstitial fluid. However during the course of drainage from 
interstitial tissues’ fluid into the lymph and lymph vessels and then into blood vessels the 
concentration of biomarker may become subject of crucial reduction. As a result, the 
concentration of specific biomarker in blood would significantly be lower than its original 
concentration in the interstitial fluid. Nevertheless, various body fluids represent more or less 
rich source of different types of biomarkers [10,11]. 
5. Proteomics of esophageal carcinoma 
With 386000 annual death, eophageal cancer is the sixth leading cause of cancer death 
worldwide [12] [13]. The incidence of esophageal cancer is geographically diverse as a large 
variation could be observed for different parts of the world. The high incidence of 
esophageal cancer in certain parts of the world indicates a role for environmental as well as 
habitual factors in addition to genetics.  
While reports indicate the highest incidence rate of esophageal cancer for northern Iran and 
certain parts in China, however, there are other high incidence areas in the world most of 
which are located in the Asian esophageal cancer belt. The Asian esophageal cancer belt 
consists of the central and eastern Asian countries including; Turkmenistan, Uzbekistan, 
Karakalpakstan (an autonomous republic in the eastern part of Uzbekistan), Kazakhstan, 
and parts of Turkey. Together these high-risk geographic areas appear to extend from north-
western Iran to China, along the path of ancient Silk Road collectively known as “Central 
Asian Esophageal Cancer Belt” (Figure 2) [14]. 
Despite recent increase in the rate of esophageal adenocarcinoma in Western world, 
esophageal squamous cell carcinoma (ESCC) still remains the most prevalent subtype of 
esophageal cancer [16]. With five-year survival rate as less than 10% prognosis of 
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esophageal cancer still remains poor. A primary cause for such high mortality is the fact that 
in most cases ESCC could be detected very late when tumor has developed well, invaded 
 
Fig. 2. The Asian esophageal cancer belt. The belt starts from eastern Anatolia in Turkey 
[15], extends through Iran to central Asian countries, China [14] and to the far east. 
surrounding tissues and organs, and therefore at an advanced stage of the disease. Surgical 
resection has shown to be ineffective in 40%-60% of cases due to low resectability of the 
disease, the presence of distant metastases, in addition to high operation risk. Additionally, 
the conventional chemo and radiotherapies are relatively ineffective which further account 
for the poor long-term survival. The patient’s survival becomes poor when the tumor 
spreads and extends through esophageal wall or when it is diagnosed with the widespread 
involvement of lymph nodes. Thus, early diagnosis and exact histological grading of the 
ESCC are critical for therapeutic management [17]. Over the past years, the molecular 
etiology of esophageal cancer was subject of extensive researches. Multiple genetic 
alterations, such as loss of tumor suppressor genes and activation of oncogenes were found 
to be associated with the development of esophageal cancer [18,19]. 
Although recent advancements such as microarray in addition to traditional molecular 
methods have been used for screening ESCC in order to find the important molecular 
alterations that ultimately result in ESCC [20-22], nevertheless, thus far target biomarkers 
applicable for the detection and therapeutic strategies and genes to act as molecular targets 
have not been well identified, indicating further limitations in the effective treatment of 
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ESCC. The high throughput and sensitive proteomic technology is hoped to open an 
effective venue for screening the novel cancer specific biomarkers for ESCC. Tissue and cell 
line based proteomics have widely been used in the study of ESCC and so far protein 
markers (biomarkers) have been identified as potential biomarkers for diagnosis of ESCC 
and possible follow-up of the treatment. Most of such identified protein molecular markers 
are those that are involved in cytoskeleton organization, metabolism, differentiation, 
apoptosis, cell growth, and metastasis as well as redox reactions. In subsequent sections, we 
present a summary of the recent achievements applying proteomics.  
6. Cytoskeleton  
Actin network is essential for several important cellular functions such as pseudopodia 
formation, motility, division, cell surface receptor movement, anchorage, and contact 
inhibition. During malignant transformation, alteration in the expression of actin 
microfilament network as well as other actin-associated proteins which are involved in the 
morphological changes and cytoskeletal organization could be seen. Among such proteins 
are tropomyosins (TPMs). As a major structural component of cytoskeletal microfilaments, 
multiple isoforms of TPMs were identified in the cultured non-muscle cells. At expression 
level different isoforms of TMP are regulated dissimilarly in tumors, implying that these 
isoforms may have different functions in cell transformation. TPM1 [23] and TPM2 [24] have 
shown to be subject of down-regulation while TPM4 [23] and TPM3 ([25], and as our 
unpublished result indicates (in a study on cell lines)) are significantly subject of up-
regulation in ESCC tissues. In addition, fusion of TPM4-ALK was observed to happen in 
ESCC [24] which results in the up regulation of anaplastic leukemia kinase. Though as a 
cytoskeletal and housekeeping protein TPM4 promoter is constantly active, the fusion 
protein (TPM4-ALK) is constantly expressed in tumor cells which results in up regulation of 
fused anaplastic leukemia kinase in the cell and its oncogenic outcome. Deregulation of 
TPM isoforms may cause an imbalance in the normal phenotype of epithelial 
microfilaments, which leads to malignant phenotype of the aberrant cells. These alterations 
may provide clues for the early detection, diagnosis, and identification of therapeutic 
targets. In addition to TPMs altered expression of members of myosin family of proteins 
have also been reported in ESCC ([24] and our unpublished results). 
Transgelin, a calponin related protein whose expression was observed to change in 
transformed cells is another member of cytoskeletal associated proteins that remarkably 
increases in ESCC. Distinct types of transgelin isoforms presents exclusively in cancer 
tissues [23]. Transgelin is an actin microfilament binding protein whose expression is 
regulated by deregulated Ras expression in a Raf independent pathway of transformation. 
Loss of transgelin in breast and colon tumors and in RIE-1 cells has also been reported [26].  
Keratins are components of intermediate filaments of cytoskeleton functioning especially in 
epithelial cells. Keratin1 and keratin 8 ([24], as well as our unpublished results on ESCC cell 
lines, [27-29]) and keratin 13 were observed to be overexpressed in ESCC, while keratin 4 
and keratin 14 are down regulated [30] in. 
Desmin is another member of intermediate filaments that subjects to down regulation in 
ESCC [16]. As a 52 kDa protein, desmin is a subunit of intermediate filaments in the tissues 
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of skeletal, smooth, and cardiac muscle [31] cells. While it is a muscle cell marker and 
important in muscle cell’s development, nevertheless its exact role is not yet known for 
other cell types and demands further studies to unravel its true function. 
Another actin binding protein is fascin that overexpression of which was observed in ESCC. 
Since overexpression of fascin was found to be associated with significant increase in the 
motility and dynamics of cell lines [16]; it could be concluded that the same consequences 
which are; the increased invasion and metastatic potential to happen for ESCC too.  
ǂ-actinins are actin binding and cross-linking proteins. Expression of alpha actinin 4 
(ACTN4) was shown to increase progressively from stage I to stage III. Clinico-pathological 
correlation using TMA (tissue microarray) revealed that overexpression of ACTN4 is 
significantly associated with the advanced tumor stage and lymph node metastasis [25] in 
ESCC. 
In addition gamma actin, tubulin alpha-1 chain, and tubulin beta-5 chain were also reported 
to be subject of change in expression in ESCC. Overexpression of these proteins was 
reported in ESCC [23]. 
7. Differentiation  
Data obtained from models of carcinogenesis suggest that alteration in the normal 
differentiation process is associated with neoplastic transformation [16]. As a result, altered 
expression of proteins, which are related to differentiation, is expected to play role in 
carcinogenesis through dedifferentiation, resistance to terminal differentiation, or alteration 
of differentiation. 
S100A8 ([32], and our unpublished data) and S100A9 [16] are the two other calcium binding 
proteins which are associated with the myeloid cell differentiation. These two proteins are 
subject of down regulation in ESCC. Recently, S100 family of proteins have received 
increasing attention as their possible involvement in several human diseases, including 
cancer. 
Annexins [33,34] were shown to play important role in esophageal carcinogenesis. Annexin 
I down regulation has reportedly been observed in ESCC ([16, 35, 36], as well as our 
unpublished results). Loss of annexin AI correlates with the early onset of tumorigenesis in 
esophageal carcinoma. It was found that expression of annexin AI to be correlated with the 
differentiation status of esophageal carcinomas as high expression of annexin AI was 
reported to occur in the poor differentiated ESCC [35,36]. In addition to annexin AI, down-
regulation of annexin A II and overexpression of annexin AIX were also observed in our 
studies on ESCC (unpublished results) and others [37-39]. 
Transglutaminases (TGases) are calcium dependent enzymes that catalyze formation of 
isopeptide bonds between amide group of glutamine and the Ɛ-amino group of lysine 
during the process of terminal differentiation in stratified squamous epithelia. It was shown 
TGases to be subject of down regulation in ESCC [16,25]. Among TGasese, the protein-
glutamine gamma-glutamyltransferase E (TGM3) plays key role in epidermal terminal 
differentiation through cross-linking structural proteins such as involucrin, loricrin, and 
small proline-rich proteins. Although the role of TGM3 in the differentiation of skin 
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keratinocytes has been well established, however, little information is available regarding its 
involvement in esophageal epithelium. TGM3 stabilizes the cornified envelope of the cells, a 
process that precedes the transition of keratinocytes to corneocytes by apoptosis [40, 41, 42]. 
It is among important molecules involved in the adhesion which is expressed by epithelial 
cells and regarded as inhibitor of invasion. As a result downregulation or loss of TGM3 
correlates with dedifferentiation, increased invasion and high incidence of lymph node 
metastasis [43]. Although the role of TGM3 has well been established in the differentiation 
of skin keratinocytes, nonetheless, little information is available regarding its involvement in 
esophageal epithelium transformation. In addition to esophageal carcinoma, 
downregulation of TGM3 was also reported in laryngeal carcinoma [44], as well as head and 
neck squamous cell carcinoma [45]. 
The other protein that reports have indicated its low expression in ESCC is galectin7, a 
member of the galectin family. The low expression of this protein in ESCC is consistent with a 
differentiation defect in keratinocytes [16]. The major functions of galectin7 include regulation 
of cell to cell and cell to matrix interactions, apoptosis and immunity. It should be noted that 
both downregulation (above) as well as upregulation of galectin7 was reported with regard to 
ESCC. Upregulation of galectin7 was reported by Zhu et al (2010) in ESCC tissues [17].  
Epidermal-type fatty acid-binding protein (E-FABP) is a member of the FABP family that 
mediates transport and utilization of fatty acids. FABPs are small cytosolic non-enzymic 
proteins that have tissue specific expression. They are involved in fatty acid signaling, 
cellular growth and differentiation. It was proposed that they play a role in cellular lipid 
uptake and transport, metabolic pathway, and regulation of protein metabolism. 
Downregulation of E-FABP in has been reported for ESCC [46].  
8. Metabolism  
Several proteins that are involved in cellular metabolism undergo overexpression in ESCC, 
for example, AKR (aldo-keto reductase) family 1, reflecting an increased metabolic and 
biosynthetic requirement of tumor cells and their possible involvement in carcinogens 
metabolism. AKR members have shown to be involved in carcinogen metabolism. As an 
example AKR can activate polycyclic aromatic hydrocarbons (PAHs) by oxidizing trans-
dihydrodiol proximate carcinogens to reactive and redox active ortho-quinones. PAHs are 
ubiquitous environmental pollutants and human carcinogens. Overexpression of AKR 
might yield more active carcinogens and result in cellular transformation and tumor 
development in ESCC [16,47].  
Glutathione transferases (GSTs) compose multigene family of dimeric enzymes of phase II 
detoxification that catalyze conjugation of glutathione to the lipophilic substrates in order to 
make them more water soluble or electrophile [48] essential for their excretion from the 
body. Since a large proportion of pro-mutagens and pro-carcinogens are lipophilic 
compounds, by conjugating them with the electrophilic glutathione they become more 
water soluble and easier targets for excretion into bile or urine. GSTs can be induced by 
many of their substrates and by some non-substrate compounds as well. For example, 
butyrate, an important luminal component produced from bacterial fermentation of dietary 
fibers, is an efficient inducer of GSTs in colonic carcinoma cell lines. M and P family of GSTs 
have a regulatory role in mitogen-activated protein (MAP) pathway and resistance to drugs. 
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In addition, overexpression of GSTs is associated with the increased resistance to apoptosis 
that could be initiated by various stimuli [49]. GSTM1, GSTP1 and GSTT2 are expressed in 
esophagus mucosa. Higher expression of GSTP1 has been observed in esophagus compared 
to other GSTs [50]. GSTM2 was found to be over-expressed in ESCC. The overexpression of 
this enzyme in ESCC might be a response to the increased GSTM substrates or to the 
bacterial metabolites in the esophagus. In addition to GSTM2, overexpression of GSTP was 
also reported in ESCC [16,51].  
Alpha enolase is a multi-functional enzyme in the glycolytic pathway which catalyzes 
formation of phosphoenol pyruvate from 2-phosphoglycerate. The expression of alpha enolase 
was seen to be elevated in ESCC tissues [52] that might indicate a higher metabolic rate as well 
as switch to glycolytic pathway as possibly the main source of providing the required energy. 
Another metabolism related protein whose expression is affected by cancer is glutamate 
dehydrogenase (mitochondrial) GLUD1. The enzyme is involved in glutaminolysis that is 
important in cancer metabolism [53]. Our observation in the cell lines prepared from ESCC 
also indicates that GLUD1 subjects to down regulation in ESCC. 
9. Redox reaction 
Accumulating evidences indicate that intracellular redox state plays important roles in 
cellular signal transduction and gene expression [54]. Reactive oxygen species (ROSs) which 
are produced during physiological processes in response to external stimuli, can affect 
intracellular redox state. At low levels, ROS modulate gene expression through modulating 
cellular redox state, however, at higher levels ROSs are extremely deleterious and 
potentially damage DNA, proteins, carbohydrates, and lipids. It has been suggested that 
ROSs play roles in all stages of carcinogenesis, including initiation, promotion, and 
progression [55,56]. In order to protect cells from oxidative radical stress, cells have 
developed defense systems that comprise proteins superoxide dismutases (SODs), catatalse, 
glutathione peroxidases, and peroxiredoxins (PRXs). The up-regulation of MnSOD and 
PRX1 in ESCC and their linear correlation with progression of disease from premalignant to 
invasive cancer reflect the cell defense effort in maintaining intracellular homeostasis. 
Interestingly, a minor down-regulation of PRX2 isoform was detected in ESCC [23,24] 
suggesting that different PRX isoforms may have slightly different functions unique to the 
esophageal neoplasms [23] . We observed PRDX5 overexpression in ESCC (unpublished 
observation). Thioredoxin peroxidase (TxP) uses thiol groups as reducing equivalent donors 
to scavenge oxidants. By reducing reactive oxygen species formation, TxP inhibits caspase 
activity and hence apoptosis. Overexpression of TxP in ESCC may increase the number of 
proliferating ESCC cells by inhibiting apoptosis [16]. 
10. Heat shock proteins 
Heat shock proteins are the highly conserved cytoprotective proteins in all species. They 
play essential role in protein folding, transport, translocation, degradation, and assembly, 
even under unstressed conditions. GRP78 is an endoplasmic reticulum (ER) chaperone 
calcium binding protein. It is involved in many cellular processes including the 
translocation of newly synthesized polypeptides across the ER membrane, facilitation of the 
folding and assembly of newly synthesized proteins, degradation of misfolded proteins 
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through proteasome, and regulation of calcium homeostasis. In addition to above functions 
GRP78 endows cancer cells ability to resist against anticancer drugs such as chemotherapy, 
antiangiogensis antibodies, and anti hormonal therapy. It was shown to be involved in 
tumor cell immune resistance, proliferation and metastasis added to its role against 
apoptosis. Thus, it is reasonable that its overexpression accompany with the increased rate 
of carcinogenesis. In accordance with these properties, elevated expression of GRP78 could 
be observed in ESCC. ESCC patients with higher expression of GRP78 show a shorter 
survival than those with low or no expression of GRP78 [52,57]. 
Calreticulin is another calcium binding endoplasmic reticulum specific protein whose up 
regulation was observed in ESCC [24,52]. It is involved in the regulation of intracellular 
calcium homeostasis and endoplasmic reticulum calcium storage capacity [52,58]. 
Calreticulin is a lectin that interacts with the nascent and newly synthesized glycoproteins. 
It functions as a molecular chaperon during folding of glycoprotein [59]. It cooperates with 
calnexin, glycoprotein glucosyltransferase and glucosidase in calnexin/calreticulin cycle of 
protein folding. Role of this cycle is engagement in selective folding of newly synthesized 
glycoproteins in the process of protein translation [60,61]. Approximately all glycoproteins 
transiently interact with one or both of these two proteins (i.e. calnexin or calreticulin) 
during maturation or degradadtion after misfolding [62,63]. 
AlphaB-Cryst is a member of the small heat shock proteins (HSPs), which are ubiquitous 
chaperone molecules related to stresses. They bind to partially denatured proteins, 
dissociating protein aggregates, modulating the correct folding, and cooperating in 
transporting newly synthesized polypeptides to the target organelles. AlphaB-Cryst is able to 
inhibit both mitochondrial and the death receptor apoptotic pathways through abolishing the 
autoproteolytic maturation of the partially processed caspase-3 intermediate. Intriguingly, 
while other HSPs were usually up-regulated in tumors, alphaB-Cryst was often down-
regulated in various cancers including in ESCC tissues. These results point out that alphaB-
Cryst plays a role distinct from other HSPs in the carcinogenesis and its underexpression 
might candidate it as a general tumor marker for various types of cancers [23]. 
gp96 and Hsp27 are the two other chaperones whose expression change have been reported in 
esophageal cancer. Reports indicate upregulation of gp96 and down regulation of Hsp27 in 
ESCC. Hsp27 and gp96 are stress-response proteins. gp96 also plays a role in tumor immunity 
[16]. In addition to gp96, overexpression of HSP70 has also been reported in ESCC [24]. 
11. Cell growth  
Several cell growth related proteins’ expression was seen to change in ESCC. PCNA is 
among such proteins whose overexoression could be observed in ESCC [16]. As a highly 
conserved protein in eukaryotes, it is essential factor for DNA replication and DNA repair. 
In addition to PCNA, upregulation of DNA directed RNA polymerase B has formerly been 
reported by our group in ESCC [24]. 
RNA binding motif proteins 8A (RBM8A), the other growth related protein is also 
overexpressed in ESCC [16]. RBMs play key role in post-transcriptional regulation of gene 
expression in eukaryotic cells and mediate mRNA processing including terminal processing 
of which; intron splicing, editing and deamination of nucleotides [64].  
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Clusterin, the so-called testosterone repressed prostate message, sulfated glycoprotein, 
complement associated protein SP-40, and complement cytolysis inhibitor, is an 80-kDa 
heterodimeric highly conserved secreted glycoprotein expressed in a wide variety of tissues 
and was found in all human fluids. It responses to a number of diverse stimuli, including 
hormone ablation and has been attributed to function in several diverse physiological 
processes such as sperm maturation, lipid transportation, complement inhibition, tissue 
remodeling, membrane recycling, cell adhesion and cell- substratum interactions, 
stabilization of stressed proteins in a folding competent state and is involved in promotion 
or inhibition of apoptosis. In addition, loss and downregulation of clusterin in ESCC, it was 
also lost or decreased in tumor cell lines and tissues [65].  
Another potential tumor suppressor protein is prohibitin that was found to be differentially 
expressed in cancerous tissues compared to the adjacent normal epithelium. Interestingly, 
while expression of prohibitin is positively correlated with the progression of precancerous 
lesions, however, it is inversely correlated with the differentiation grade of squamous cell 
carcinoma of esophagus. The expression of prohibitin drops with dedifferentiation of ESCC. 
This pattern of expression implies that prohibitin may play different roles in different stages 
of esophageal tumorigenesis [23].  
Eukaryotic translation initiation factor 1 a (eIF-1a), reticulocalbin and transmembrane 
protein 4 are three other proteins that overexpress in ESCC [16]. eIF-1a stabilizes Met-tRNA 
to the 40S ribosomal subunit, thus prevents pre-maturation association of 40S ribosomal 
subunit to 60S subunit of ribosome [66]. eIF-1a along with other eIFs stimulate decoding of 
AUG start codon in mRNA [67].  
Reticulocalbin is a calcium binding protein located in the endoplasmic reticulum lumen. 
Overexpression of this protein plays a role in tumorogenesis, tumor invasion and resistance 
to drug [68,69]. 
12. Metastasis  
Cancer cells escape the primary tumor mass and penetrate into the surrounding tissues or 
tissues at far distant through the process of invasion and metastasis, the two processes that 
require degradation of extracellular matrix and/or basement membranes. The key 
molecules involved in the degradation of these structures are cysteine, serine, and aspartic 
acid protease as well as matrix metalloproteinases (MMPs). MMPs contains collagenases 
(MMP-1, MMP-8, MMP-13, MMP-18), gelatinases (MMP-2, MMP-9), stromelysins (MMP-3, 
MMP-10, MMP-11) matrilysins (MMP-7, MMP-26) mating type (MMP-14, MMP-15, MMP-
16, MMP-24, MMP-17, MMP-25) and non-classified (RASI-1, enamelysin 
) [70]. Generally, gelatinases are more often observed in tumor tissues. It seems that they are 
involved more in the invasion rather than other members of matrix metalloproteinases 
[71,72]. High expression of MMP-1 [73], MMP-7 [74], MMP-11 [75] is associated with the 
worse prognosis of tumors, while MMP-9 and MT1-MMP are involved in the depth of 
invasion [76,77]. MMP-2 and MMP-3 were found to be correlated with the lymph node 
metastasis in ESCC [78]. 
Down-regulation of neutrophil elastase inhibitor and SCCA1 (below) in ESCC was among 
other observation by proteomic studies. Neutrophil elastase is an inflammatory protein that is 
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mainly produced by neutrophils. The protease degrades extracellular matrix thereby increases 
ability of neutrophils to infiltrate into the tissues. Neutrophil elastase might also be released by 
some cancer cells to serve a similar function. Low expression of elastase inhibitor in ESCC 
would result in an increased enzyme activity, facilitating tumor invasion and metastasis.  
Squamous Cell Carcinoma Antigens (SCCAs), are members of serine protease inhibitors 
(serpins) [79] superfamily that strong expression of which could be observed in different 
epithelial cancers. Two different isoforms of SCCA are encoded by two highly homologous 
genes SCCA1 and SCCA2 [80]. Both the SCCA1 and SCCA2 proteins are physiologically 
present in the suprabasal layers of normal stratified squamous epithelium[81]. SCCA1 [23] 
was shown to inhibit papain like cysteine proteinases, cathepsin S, K, and L. Serpins are 
involved in the multiple cellular biological processes including tumor cell invasion, cellular 
differentiation, and apoptosis. SCCA1 may function intra as well as extracellularly, serving 
as a cytoprotective mediator [16,23].  
APA-1, a zinc finger protein, was shown to be overexpressed in ESCC. APA-1 is a 
transcription factor which activates transcription of matrix remodeling genes such as matrix 
metalloproteinase 1 (MMP-1 ) during fibroblast senescence [52]. The same role for APA-1 
overexpression could be envisaged for esophageal cancer.  
13. Apoptosis  
Apoptosis is a major barrier for cancer cells that they must have to overcome in order to 
survive. The modest increase observed in COX-2 and p53 protein expression with 
progression from normal to dysplasia suggests that these markers may be the most 
informative in the more advanced state of neoplasias [17,30]. Cyclooxygenases (Cox-1 and 
Cox-2) are enzymes which are involved in the formation of prostaglandins from arachidonic 
acid. While Cox-1 is constitutively expressed; Cox-2 is induced by cytokines, tumor 
promoters, growth factors and viral induced transformation. Cox-2 was found to be 
expressed in various malignant tumors [82]. Expression of Cox-2 could be induced by p53. 
In turn, Cox-2 negatively affects p53 activity through physical interaction with p53. Cox-2 is 
a positive regulator of growth while p53 is a negative regulator of growth thus increasing 
expression of Cox-2 by p53 seems to be a controlling event of growth by creating a balance 
between induction and inhibition of cellular division. It is suggested that p53-dependent 
induction of Cox-2 abate apoptotic and growth inhibitory effect of p53 [83].  
14-3-3 protein sigma, also known as stratifin or HME-1, has recently reported to be down 
regulated in ESCC. It is transactivated by p53 in response to DNA damage and negatively 
regulates both G1/S and G2/M cell cycle progression. Overexpression of stratifin increases 
stabilization of p53 through blocking Mdm2 mediated p53 ubiquitination and enhanced 
oligomerization of p53, leading to the increased p53 transcriptional activity. Additionally, 
expression of stratifin inversely correlates with the differentiation grade of ESCC indicating 
that malignant cells arising from esophageal epithelium may lose stratifin in progressive 
dedifferentiation [23]. Stratifin is a checkpoint protein that causes G2 arrest following to 
DNA damage. Inactivation of this protein; mainly by methylation, was reported in some 
tumors. Likely loss of this protein impairs the function of G2/M checkpoint results in the 
accumulation of genetic defects and ultimately cancer [84]. 
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Table 1 represents proteins that were identified using proteomic based methods in ESCC 
and we discussed here. These are not the only proteins identified with regard to ESCC, 
though other proteins could also be found in other literatures. Here we focused on some 
proteins as examples for documenting the applicability of proteomic based methodologies 
in the molecular etiology of cancers and among which esophageal cancer in particular. A 
long list of proteins for ESCC could be found in literatures that are far from scope of the 
present book chapter. We propose that in future studies attempts to be focused on 
narrowing down the list of proteins to as small number and to as tissue specific as possible 
till each of such proteins could be correlated with a specific type of cancer. Such a narrowing 
down is important from that respect that makes detection and prediction of specific type of 
cancer possible before the onset of the disease, especially by using such proteins as markers 
in body fluids, body secretions and excretions and other rout of discharge from the body. 
Fortunately, recent reports indicate the potential of proteomic based studies in correlating 
and establishing fine relationship between the expression patterns of several proteins with 
the stage of carcinogenesis as well as differentiation or grade of cancer. Among such reports 
are papers published by Qi and colleagues [23] and Nishimori, et al. [85] that showed well 
such a correlation. These proteins have significant clinical value since they could be used as 
molecular markers in order to evaluate the tumor per se and prognosis for evaluating the 
efficacy of the treatment as well as prediction of recurrence, etc. (figure 3).  
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Table 1. Proteins identified by proteomics in ESCC and discussed in the text. 
 
Fig. 3. Correlation between expression patterns of several proteins identified by 2DE and 
differentiation status (A), grade (B) or the degree of lesion (C) in ESCC. Numbers in the 
parenthesis indicate the spot number in 2DE gel pattern explained in the text by the authors. 
A well correlation could be established for stratifin, TPM4, peroxiredoxin and the other 
member of redox family of proteins; peroxiredoxin1, as well as Mn-SOD with the degree of 
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the disease progression. Other proteins show more or less the same pattern of expression 
change (adapted from Takanori Nishimori, et al [85]).  
14. Conclusion 
The complexity of the carcinogenesis in addition to the dynamics of the protein constituent 
of the cells demand new approaches for the analysis of the molecular etiology of cancers and 
among which ESCC for establishing appropriate strategies of their successful detection, 
treatment, and follow up. Proteomics is a powerful mean of gene expression analysis 
applicable both at translational as well as posttranslational level. In addition it could be used 
for studying protein-nucleic acid, or protein-drug interaction, along with vast other 
applications. As a result, proteomics could be an appropriate complement for the gene 
expression based analyses. It enables to put further steps of information ahead which is the 
entire genes being expressed in a cell or tissue at a given time and under specific condition. 
So far many proteins in different steps of carcinogenesis have been identified that found to 
be subject of alteration in carcinogenesis. Accumulating data indicate that proteomics could 
be an efficient approach for the identification of molecular alterations in ESCC 
carcinogenesis in addition to other cancers.  
The data generated by proteomics in ESCC has so far lead us to the identification of a set of 
proteins, which are involved in the different stages of ESCC carcinogenesis. These proteins 
are not only related to the alterations in the structure but also to the function of ESCC 
among which cell growth and division along with apoptosis and invasion. Moreover, 
several of such identified proteins were also found to be as appropriate biomarkers of ESCC, 
which authenticates the efficacy of the proteomic based strategies in clinical investigations 
and practical application. It is expected that proteomic evaluation of tissues and body fluids 
could open a venue to the achievement of the proper approaches of the assessment of the 
overall status of health and prognosis of cancers including ESCC. 
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